Dr. Lan Bo Chen



Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He is the author of over 200 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Synta Pharmaceuticals and Sequential Medicine.

Dr. Chen currently serves as the Chairman of CHO Pharma, a Taiwan-based biopharmaceutical company focused on the development and commercialization of proprietary glycan engineering technologies.
 Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates. Dr. Chen was elected as an academician of the Academia Sinica of Taiwan in 1996. He received his B.S. in chemistry from National Taiwan University and Ph.D. in cell biology from the Massachusetts Institute of Technology.